Ross procedure: valve function, clinical outcomes and predictors after 25 years’ follow-up

• Published in: Current problems in cardiology Vol. 49; no. 4; p. 102410
• Main Authors: Pardo González, Laura, Ruiz-Ortiz, Martín, Delgado, Mónica, Rodriguez, Sara, Villalba, Rafael, Merino, Carlos, Casares, Jaime, Mesa, Dolores, Suárez de Lezo, José, Pan, Manuel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-04-2024
• Subjects: Aortic valve; Homograft; Pulmonary autograft; Ross procedure; Valve surgery; Homograft; Ross procedure; Pulmonary autograft; Valve surgery; Aortic valve; pulmonary autograft; aortic valve; homograft
• ISSN: 0146-2806; 1535-6280
• DOI: 10.1016/j.cpcardiol.2024.102410

To describe long-term outcomes of the Ross procedure in a single center and retrospective series after 25 years follow-up.
From 1997-2019 we included all consecutive patients who underwent Ross procedure at our center. Clinical and echocardiographic evaluations were performed at least yearly. Echocardiographic valvular impairment was defined as at least moderate autograft or homograft dysfunction. Reintervention outcomes included surgical and percutaneous approach.
151 Ross procedures were performed (mean age 28±12years, 21 %<16years, 70 %male). After 25 years follow-up (median 18 years, interquartile range 9–21, only 3 patients lost) 12 patients died (8 %); Autograft, homograft or any valve dysfunction were present in 38(26 %), 48(32 %) and 75(51 %), respectively; and reintervention in 22(15%), 17(11%) and 38(26 %) respectively. At 20 years of follow-up, probabilities of survival free from autograft, homograft or any valve dysfunction were 63 %, 60 % and 35 %; and from reintervention, 80 %, 85 % and 67 %, respectively. The learning curve period (first 12 cases) was independently associated to autograft dysfunction (HR 2.78, 95 %CI:1.18-6.53, p = 0.02) and reintervention (HR 3.76, 95 %CI: 1.46-9.70, p = 0.006). Larger native pulmonary diameter was also an independent predictor of autograft reintervention (HR 1.22, 95 %CI:1.03-1.45, p = 0.03). Homograft dysfunction was associated with younger age (HR 5.35, 95 %CI: 2.13-13.47, p<0.001) and homograft reintervention, with higher left ventricle ejection fraction (HR 1,10, 95 %CI:1.02-1.19, p<0.02).
In this 25 years’ experience after the Ross procedure, global survival was high, although autograft and homograft dysfunction and reintervention rates were not negligible. Clinical and echocardiographic variables can identify patients with higher risk of events in follow up.
[Display omitted]